BRCA1 and Lynch syndrome: Genetic testing can identify patients, for example those with BRCA1, BRCA2, and Lynch Syndrome gene PGVs, who may benefit from FDA approved targeted therapy with PARP inhibitors and immune check point blockade, respectively6.